Danske Bank A S Invests $9.94 Million in United Therapeutics Corporation $UTHR

Danske Bank A S bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 18,349 shares of the biotechnology company’s stock, valued at approximately $9,942,000.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $2,868,735,000. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC boosted its position in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on UTHR shares. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada reduced their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,185,729.06. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 442,575 shares of company stock valued at $239,326,330. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $513.12 on Friday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The company has a market cap of $22.01 billion, a P/E ratio of 18.36, a PEG ratio of 1.76 and a beta of 0.59. The business’s 50-day simple moving average is $533.08 and its 200-day simple moving average is $537.36.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 earnings per share. As a group, analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.